FDA Clearance Tracker · P150013-S017
PD-L1 IHC 22C3 pharmDx
Last checked: Nov 20, 2026Latest source record: Mar 19, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Mar 19, 2020
Approved
Time to decision
279 days
Received Jun 14, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P150013-S017
- Device name
- PD-L1 IHC 22C3 pharmDx
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Jun 14, 2019
- Decided
- Mar 19, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P150013
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approved to migrate the PD-L1 IHC 22C3 pharmDx assay for NSCLC indication for use on the Dako Omnis automated staining system per approval letter.
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.